TMO · Thermo Fisher Scientific Inc.

Summary

Thermo Fisher Scientific Inc. announced the completion of its acquisition of Clario Holdings, Inc. for $8.875 billion in cash plus additional payments on March 24, 2026. The deal integrates Clario's clinical trial data solutions into Thermo Fisher's Laboratory Products and Biopharma Services segment, with expected accretion to adjusted EPS and operating margins.

Key takeaways

• Acquisition of Clario Holdings, Inc. completed on March 24, 2026
• Cash purchase price of $8.875 billion
• Additional $125 million payable in January 2027
• Up to $400 million earn-out based on 2026-2027 performance
• Clario joins Laboratory Products and Biopharma Services segment
• Expected $0.45 adjusted EPS contribution in first year post-close
• $175 million adjusted operating income from synergies by year 5